Please assess the completion status of the following clinical trial:

Trial Title: Study of Temozolomide to Treat Newly Diagnosed Brain Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Tumor characteristics adequate for stereotactic radiosurgery:~1. 1-3 newly diagnosed, previously untreated, brain metastases~2. Each tumor measuring a size less than or equal to 3 cm~3. No other contraindications to stereotactic radiosurgery~Systemic parameters adequate for temozolomide following stereotactic radiosurgery:~1. Histological confirmation of systemic malignancy (brain confirmation not required)~2. Male or female 18 years of age or older~3. Negative pregnancy test (if of childbearing potential)~4. Any number of previous recurrences will be allowed~5. Karnofsky Performance Status \> 60~6. Hematocrit \> 30,000~7. White blood cell count \> 1,500~8. Platelet \> 100,000~9. Absolute Neutrophil Count \> 1,000~10. Bilirubin \< 1.5 x upper limits of normal~11. Transaminases (ALT and AST) \< 1.5 x upper limits of normal~12. Creatinine \< 1.5 x upper limits of normal~13. Adequate medical health to participate in this study~14. Adequate documentation of menopause (natural/surgical) or patient commitment to routine use of reliable birth control (barrier/hormonal)~15. Ability to read and understand the informed consent document~16. Ability and willingness to follow all requirements of the study including following all directions, taking medication as prescribed and completing all diaries and forms~17. No other contraindications to temozolomide (severe organ dysfunction, immunosuppression, etc.)~18. Medical stability and/or recovery from effects of stereotactic radiosurgery~Exclusion Criteria:~1. Karnofsky Performance Status \< 60~2. Hematocrit \< 30,000~3. White blood cell count \< 1,500~4. Platelet \< 100,000~5. Absolute Neutrophil Count \< 1,000~6. Bilirubin \>1.5 x upper limits of normal~7. Transaminases (ALT and AST) \> 1.5 x upper limits of normal~8. Creatinine \> 1.5 x upper limits of normal~9. Inability to undergo gadolinium-contrasted MRIs, including severe claustrophobia or insufficient allergy prophylaxis~10. Germ cell, leukemia, and lymphoma histologies will be excluded~11. Prior chemotherapy or radiotherapy for brain metastases (prior resection and steroids are allowed)~12. Contraindications to radiosurgery or temozolomide chemotherapy~13. Uncontrolled systemic malignancy~14. Chemotherapy or other systemic therapy for systemic malignancy within a specified time of temozolomide initiation, depending on half-life of agent:~    1. Cytotoxic chemotherapy within the previous 4 weeks~   2. Nitrosurea (CCNU, BCNU) within the previous 6 weeks~   3. Gliadel or temozolomide within the previous 4 weeks~   4. Bevacizumab or other antiangiogenic agent within the previous 4 weeks~   5. Other targeted molecular or antibody agent within the previous 4 weeks~   6. Hormonal agent within the previous 2 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Temozolomide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues